NewsBytes
    Hindi Tamil Telugu
    More
    In the news
    Narendra Modi
    Amit Shah
    Box Office Collection
    Bharatiya Janata Party (BJP)
    OTT releases
    Hindi Tamil Telugu
    NewsBytes
    User Placeholder

    Hi,

    Logout


    India Business World Politics Sports Technology Entertainment Auto Lifestyle Inspirational Career Bengaluru Delhi Mumbai Visual Stories Find Cricket Statistics Phones Reviews Fitness Bands Reviews Speakers Reviews

    Download Android App

    Follow us on
    • Facebook
    • Twitter
    • Linkedin
     
    Home / News / India News / Remdesivir reportedly approved for COVID-19 treatment in India
    Remdesivir reportedly approved for COVID-19 treatment in India
    1/7
    India 3 min read

    Remdesivir reportedly approved for COVID-19 treatment in India

    By Shubham Sharma
    Jun 02, 2020
    11:49 am
    Remdesivir reportedly approved for COVID-19 treatment in India

    Remdesivir has been approved by India's top drug regulator for "restricted emergency use" on COVID-19-infected adults and children. The approval process of the drug, according to PTI's sources familiar with the development, was fast-tracked in light of the sporadic spike in cases of the disease across India, and the deaths stemming from them. Here is all you need to know about it.

    2/7

    First, what is Remdesivir?

    Developed by Gilead Life Sciences, Remdesivir is an anti-viral drug that is being closely monitored as a potential treatment for COVID-19 in clinical trials around the world. In the US, it helped sick patients recover in 11 days, four days sooner than other placebo-involved treatments, and was subsequently cleared by the Food and Drug Administration (FDA) for emergency use.

    3/7

    Other studies have also shown positive results

    A separate study published in The New England Journal of Medicine had also found that two out of three critically ill COVID-19 patients who were on oxygen support showed signs of improvement with Remdesivir.

    4/7

    Approval from Drugs Controller General of India

    Now, given the spike in COVID-19 cases and the lack of a proven therapy, Dr. VG Somani, the Drugs Controller General of India, has approved Remdesivir for "restricted emergency use." As part of this, sources say, the drug will be used to treat suspected or laboratory-confirmed cases of COVID-19 in adults and children hospitalized with severe symptoms, with appropriate safeguards.

    5/7

    Now, Remdesivir can be purchased from the market

    With this, the COVID-19 drug can be sold "on the prescription of specialists for use in [a] hospital or institutional set-up." The approval was fast-tracked by special provisions under the New Drug and Clinical Trial Rules, 2019, which allows for skipping clinical trials. However, Dr. Somani did consult the expert committee of the Central Drugs Standard Control Organization he heads before clearing the medication.

    6/7

    Only 5-day regimen approved

    That said, it must be noted that the medicine, which is administered as an injection, has been approved for a maximum 5-day regimen. "Administering Remdesivir for 10 days...doesn't have any beneficial effects, so why should patients consume it for an additional five days? There is also a potential risk of mortality rate increasing with extended use," a Health Ministry official told The Indian Express.

    7/7

    India has nearly 2 lakh COVID-19 cases

    The move to approve Remdesivir comes as India's COVID-19 cases inch closer to the 2 lakh mark. So far, at least 5,606 people in the country have died from the disease.

    Facebook
    Whatsapp
    Twitter
    Linkedin
    Related News
    United States of America
    Central Drugs Standard Control Organization (CDSCO)
    Drugs Controller General of India
    Remdesivir
    COVID-19 Vaccine

    United States of America

    'Chintu Ka Birthday': An Indian family-drama set in wartime Iraq All India Bakchod
    As protests continued, Trump was briefly taken to underground bunker Donald Trump
    US cities order curfews amid protests against George Floyd's death White House
    Trump postpones G7 Summit until September; invites India, Russia, others Donald Trump

    Central Drugs Standard Control Organization (CDSCO)

    #GoodNews: Pune's Mylab approved to make COVID-19 test kits India
    SC seeks Center's response on faulty hip implants by J&J Supreme Court Of India
    Health Ministry to rename drug regulator CDSCO; invites suggestions India
    Government plans to make companies responsible for drug regulation violations India

    Drugs Controller General of India

    GSK recalls popular antacid Zinetac amid concerns over cancer-causing substance India
    India may have a vaccine for dengue by 2019-end India
    SII gets nod for Oxford COVID vaccine phase 2/3 trials Oxford
    Coronavirus: What is the 'Feluda' test? How does it work? DNA

    Remdesivir

    Noida-based Jubilant to make COVID-19 drug Remdesivir in India COVID-19
    India gears up to develop key COVID-19 drug: Details here Hindustan Times
    New COVID-19 drug has 'clear cut' positive effect: Dr. Fauci Anthony Fauci
    Health Ministry adds loss of smell, taste to COVID-19 symptoms World Health Organization

    COVID-19 Vaccine

    No quarantine for fully vaccinated Indians in UK from Monday India
    COVAXIN recommended by expert panel for children aged 2-18 years Health & Wellness
    Vaccination for children can wait as trial still underway: Expert COVID-19
    COVID-19: India reports 15K+ new cases, 231 more deaths Narendra Modi
    Next News Article

    Love India News?

    Subscribe to stay updated.

    India Thumbnail
    Indian Premier League (IPL) Celebrity Hollywood Bollywood UEFA Champions League Tennis Football Smartphones Cryptocurrency Upcoming Movies Premier League Cricket News Latest automobiles Latest Cars Upcoming Cars Latest Bikes Upcoming Tablets
    About Us Privacy Policy Terms & Conditions Contact Us Ethical Conduct Grievance Redressal News News Archive Topics Archive Download DevBytes Find Cricket Statistics
    Follow us on
    Facebook Twitter Linkedin
    All rights reserved © NewsBytes 2023